Singapore Association of Pharmaceutical Industries Supports Singapore Through These Tough Times

September 3, 2020, SINGAPORE —The 34 member companies of the Singapore Association of Pharmaceutical Industries (SAPI) are humbled and honored to be among the industries recognized by the Prime Minister for our contribution to the health and economy of Singapore and the region, in his September 2 speech to Parliament.

SAPI appreciates how the Prime Minister noted the long-term commitment the biopharmaceutical industry has shown, citing as an example of how pharmaceutical companies began investing in Singapore two to three decades ago, through manufacturing plants first, before setting up regional HQs and research labs here as they expanded. This also ultimately helped in the upskilling of Singaporeans working in the industry and reaching senior roles.

Deputy Prime Minister Heng Swee Keat also referenced the importance of the biopharmaceutical industry for Singapore, referring to us as a “bright spot” in the economy. Such outcomes are achieved through the continuous cooperation and dialogue between SAPI members and the relevant government agencies that enabled our labor force, logistics, and supply chain to all continue in a largely uninterrupted manner throughout the crisis. Additionally, the policy environment that first attracted our companies to Singapore has also been a key component of our success and continued investment.

SAPI and our members affirm that we stand together with Singapore. We are grateful for the support extended to the sector now and in the future as we continue to navigate through the pandemic, and look forward to working together in growing the local biopharmaceutical ecosystem as we emerge from this crisis of a generation.

For media queries, please contact:
Ms. Christina Teo
Executive Director
Singapore Association of Pharmaceutical Industries
Email: christina.teo@sapi.org.sg
Tel: 6738 0966

About SAPI

Singapore Association of Pharmaceutical Industries (SAPI) was founded in 1966 and was initially known as the Pharmaceutical Trade Association. In 1975, the Association changed its name to encompass a wider spectrum of pharmaceutical related business into the Association— namely the distributors, manufacturers, representative offices and affiliated companies.
Currently, SAPI comprises 41 members of which 34 are global biopharmaceutical companies in Singapore, with its members employing close to 10,000 people in the country. SAPI aims to make innovative medicine accessible to patients in Singapore. SAPI achieves this through a sustainable and valued partnership with healthcare professionals and providers, government, patient group stakeholders, and a reputation of consistent ethical behavior.